Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime

Diane M. Gomes, Carmen Smotherman, Amy Birch, Lori Dupree, Bethany J. Della Vecchia, D. Kraemer, Christopher A. Jankowski

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p

Original languageEnglish
Pages (from-to)662-669
Number of pages8
JournalPharmacotherapy
Volume34
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Vancomycin
Acute Kidney Injury
Therapeutics
Incidence
tazobactam drug combination piperacillin
cefepime
Kidney

Keywords

  • acute kidney injury
  • cefepime
  • nephrotoxicity
  • piperacillin-tazobactam
  • vancomycin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Gomes, D. M., Smotherman, C., Birch, A., Dupree, L., Della Vecchia, B. J., Kraemer, D., & Jankowski, C. A. (2014). Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy, 34(7), 662-669. https://doi.org/10.1002/phar.1428

Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. / Gomes, Diane M.; Smotherman, Carmen; Birch, Amy; Dupree, Lori; Della Vecchia, Bethany J.; Kraemer, D.; Jankowski, Christopher A.

In: Pharmacotherapy, Vol. 34, No. 7, 2014, p. 662-669.

Research output: Contribution to journalArticle

Gomes, DM, Smotherman, C, Birch, A, Dupree, L, Della Vecchia, BJ, Kraemer, D & Jankowski, CA 2014, 'Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime', Pharmacotherapy, vol. 34, no. 7, pp. 662-669. https://doi.org/10.1002/phar.1428
Gomes, Diane M. ; Smotherman, Carmen ; Birch, Amy ; Dupree, Lori ; Della Vecchia, Bethany J. ; Kraemer, D. ; Jankowski, Christopher A. / Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. In: Pharmacotherapy. 2014 ; Vol. 34, No. 7. pp. 662-669.
@article{e70935ed55144af98477b7bccab6a10b,
title = "Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime",
abstract = "Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8{\%}) compared with the cefepime-vancomycin group (12.5{\%}) in the unmatched analysis (p",
keywords = "acute kidney injury, cefepime, nephrotoxicity, piperacillin-tazobactam, vancomycin",
author = "Gomes, {Diane M.} and Carmen Smotherman and Amy Birch and Lori Dupree and {Della Vecchia}, {Bethany J.} and D. Kraemer and Jankowski, {Christopher A.}",
year = "2014",
doi = "10.1002/phar.1428",
language = "English",
volume = "34",
pages = "662--669",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime

AU - Gomes, Diane M.

AU - Smotherman, Carmen

AU - Birch, Amy

AU - Dupree, Lori

AU - Della Vecchia, Bethany J.

AU - Kraemer, D.

AU - Jankowski, Christopher A.

PY - 2014

Y1 - 2014

N2 - Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p

AB - Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p

KW - acute kidney injury

KW - cefepime

KW - nephrotoxicity

KW - piperacillin-tazobactam

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84903883207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903883207&partnerID=8YFLogxK

U2 - 10.1002/phar.1428

DO - 10.1002/phar.1428

M3 - Article

VL - 34

SP - 662

EP - 669

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 7

ER -